Role of Surgery in Patients with Recurrent, Metastatic, or Unresectable Locally Advanced Gastrointestinal Stromal Tumors Sensitive to Imatinib: A Retrospective Analysis of the Spanish Group for Research on Sarcoma (GEIS)-Reference-Cited by-同舟云学术

Role of Surgery in Patients with Recurrent, Metastatic, or Unresectable Locally Advanced Gastrointestinal Stromal Tumors Sensitive to Imatinib: A Retrospective Analysis of the Spanish Group for Research on Sarcoma (GEIS)

Published:2015-01-22 Issue:9 Volume:22 Page:2948-2957
ISSN:1068-9265
Container-title:Annals of Surgical Oncology
language:en
Short-container-title:Ann Surg Oncol

Author:

Rubió-Casadevall Jordi, ,Martinez-Trufero Javier,Garcia-Albeniz Xabier,Calabuig Silvia,Lopez-Pousa Antonio,del Muro Javier Garcia,Fra Joaquin,Redondo Andrés,Lainez Nuria,Poveda Andrés,Valverde Claudia,De Juan Ana,Sevilla Isabel,Casado Antonio,Andres Raquel,Cruz Josefina,Martin-Broto Javier,Maurel Joan

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Surgery

Link

http://link.springer.com/content/pdf/10.1245/s10434-014-4360-8.pdf

Reference22 articles.

1. Nilsson B, Bümming P, Meis-Kindblom JM, et al. Gastrointestinal stromal tumors: the incidence, prevalence, clinical course and prognostication in the pre-imatinib mesylate era: a population based study in western Sweden. Cancer. 2005;103(4):821–9.

2. Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science. 1998;279:577–80.

3. Heinrich MC, Corless CL, Duensing A, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science. 2003;299:708–10

4. Blanke CD, Demetri GD, von Mehren M, et al. Long-term results from a randomized phase II trial of standard-versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing kit. J Clin Oncol. 2008;26:620–5.

5. Green S, Weiss GR. Southwest Oncology Group standard response criteria, end point definitions, and toxicity criteria. Invest New Drugs. 1992;10:239–53

Cited by 52 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ibero-American Consensus for the Management of Peritoneal Sarcomatosis: Updated Review and Clinical Recommendations;Cancers;2024-07-25

2. Survival outcomes and prognostic factors of advanced gastrointestinal stromal tumors: in the era of multiple tyrosine kinase inhibitors;Journal of Gastrointestinal Oncology;2024-06

3. English version of Japanese Clinical Practice Guidelines 2022 for gastrointestinal stromal tumor (GIST) issued by the Japan Society of Clinical Oncology;International Journal of Clinical Oncology;2024-04-13

4. Cytoreductive surgery in patients with recurrent or metastatic gastrointestinal stromal tumors sensitive to imatinib: a retrospective analysis of two Russian cancer centers;Translational Gastroenterology and Hepatology;2024-01

5. Surgery plus TKIs therapy for gastrointestinal stromal tumors;Postępy Higieny i Medycyny Doświadczalnej;2024-01-01